Navigation Links
Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
Date:5/11/2012

s, decisions by regulatory authorities as to whether and when to approve drug applications, and general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussed in Auxilium's Annual Report under the heading "Risk Factors" on Form 10-K for the year ended December 31, 2011, and Form 10-Q for the quarter ended March 31, 2012, which are on file with the Securities and Exchange Commission (the "SEC") and may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov or by means of Auxilium's home page on the Internet at http://www.Auxilium.com under the heading "For Investors -- SEC Filings." There may be additional risks that Auxilium does not presently know or that Auxilium currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements.

In addition, forward-looking statements provide Auxilium's expectations, plans or forecasts of future events and views as of the date of this release. Auxilium anticipates that subsequent events and developments will cause Auxilium's assessments to change. However, while Auxilium may elect to update these forward-looking statements at some point in the future, Auxilium specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Auxilium's assessments as of any date subsequent to the date of this release.For More Information, Contact:James E. Fickenscher / CFOWilliam Q. Sargent, Jr. / V.P., IR  Auxilium Pharmaceuticals, Inc.Auxilium Pharmaceuticals, Inc.(484) 321-59(484) 321-5900

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
3. BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update
4. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
5. Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
6. Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference
7. Auxilium Pharmaceuticals Reports Preliminary Fourth Quarter 2010 Net Revenue and Announces 2011 XIAFLEX Revenue Guidance
8. Auxilium Pharmaceuticals to Present at the 2011 Citi Annual Global Healthcare Conference
9. Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. Auxilium Pharmaceuticals, Inc. Completes Enrollment of XIAFLEX® Phase III Double-Blind Studies for Peyronies Disease
11. Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... -- The U.S. Department of Health and Human Services (HHS) ... Case Medical Center Seidman Cancer Center totaling $4.7 million ... care for patients with complex cancer. ... unique model developed at UH to enhance care for ... demonstrated need for high health care utilization.  ...
(Date:7/10/2014)... INC. (NYSE: RMD ) today announced that it ... 30, 2014 results on Thursday, July 31, 2014, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, ... today announced it has completed the sale to Galderma ... Dysport owned or held by Valeant for $1.4 billion ... Nestle S.A, which recently completed its acquisition of Galderma. ... divestiture of our products to a company that is ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... levels following 4 weeks of, treatment with R7128 1500mg and Pegasys(R) plus ... tolerability comparable to ... - Conference Call Scheduled for 4:00PM ET Today -, PRINCETON, N.J., ... of a 4-week Phase 1,clinical trial to evaluate two oral dose levels ...
... Duration of ... Neutropenia- ... Jan. 7 Maxygen, Inc.,(Nasdaq: MAXY ) today announced positive progress in ... the trial include the following:, -- Patients in the initial 10 ...
Cached Medicine Technology:Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 2Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 3Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 4Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 5Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 6Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF 2Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF 3Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF 4
(Date:7/11/2014)... UC San Francisco shows that an "expressive therapy" ... women living with HIV disclose their health status ... safety and quality of their relationships., "Medication alone ... Edward L. Machtinger, MD, director of the Women,s ... our patients are on effective antiretroviral therapy but ...
(Date:7/11/2014)... July 11, 2014 Bedros Keuilian is known ... title he’s earned by founding the fast-selling fitness franchise in ... their businesses. He works with successful boot camp owners on ... on the traits of the most successful boot camp owners ... important qualities. , “I’ve worked with and coached some of ...
(Date:7/11/2014)... When the mercury rises, heat can strain the ... heart, takes on a heavier load in hot weather to ... of the Harvard Men's Health Watch . , For ... than knowing their limits and drinking enough fluids. But what ... more sensitive to the heat," says Dr. Joanne Foody, Director ...
(Date:7/11/2014)... 11, 2014 As reported by Forbes ... Cocaine: Are Genetics To Blame (6/30), Indino Downey has ... and paraphernalia to smoke it with. His father, well-known ... his son inherited from him may have something to ... the news during the 1980s and 1990s for substance ...
(Date:7/11/2014)... Timex, the leader in outdoor and sports performance ... Network, the brand’s new online content portal which will ... and special product offers for consumers. , The ... the Timex IRONMAN watch brand and will serve as ... The hub will reflect the active lifestyle of Timex ...
Breaking Medicine News(10 mins):Health News:'Expressive therapy" intervention assists women living with HIV 2Health News:Fitness Boot Camp Marketing Expert Bedros Keuilian Shares the Top Three Traits of Successful Boot Camp Owners 2Health News:Fitness Boot Camp Marketing Expert Bedros Keuilian Shares the Top Three Traits of Successful Boot Camp Owners 3Health News:Take Common Sense Steps to Stay Safe This Summer, from the July 2014 Harvard Men's Health Watch 2Health News:Take Common Sense Steps to Stay Safe This Summer, from the July 2014 Harvard Men's Health Watch 3Health News:Roberty Downey's Son Arrested For Cocaine 2Health News:Timex Announces Launch of Timex Performance Network 2
... All PETCO stores nationwide will host a free pet nutrition, ... experts on Saturday, November 14 at 2 p.m. During the 30-minute, ... the nutritional needs of, their dogs ... good pet nutrition, receive an assessment of their individual, ...
... the University of Florida Proton Therapy Institute have formed a ... announcement follows the approval of the first clinical study to ... in children younger than 3 years old. ... receive proton therapy at the UF Proton Therapy Institute in ...
... issue of European Urology , the official journal ... entitled ,Are Infertile Men Less Healthy than Fertile Men? ... Salonia et al. The conclusion is that male factor ... as objectively scored with the hospital-based Charlson Comorbidity Index. ...
... In the construction industry, respiratory disease, often leading to ... major public health concern. Studies led by Deborah ... Construction, have shown that specific types of sanding tools ... these health hazards, yet the industry,s usage of the ...
... The first human embryonic stem cell treatment approved by ... limb function in rats with neck spinal cord injuries ... people with cervical damage. In January, the U.S. Food ... permission to test the UC Irvine treatment in individuals with ...
... ACCRA, Ghana -- The lives of almost 4 million ... saved every year if well-established, affordable health care interventions ... report by the national science academies of seven African ... knowledge to save lives, says the report, which calls ...
Cached Medicine News:Health News:St. Jude and UF Proton Therapy Institute to begin proton therapy clinical trial 2Health News:European Urology: Male factor infertility associated with comorbidities 2Health News:Dust control research leads to a NIOSH grant to facilitate adoption of hazard controls 2Health News:Dust control research leads to a NIOSH grant to facilitate adoption of hazard controls 3Health News:UCI embryonic stem cell therapy restores walking ability in rats with neck injuries 2Health News:Using science to save lives of mothers and children in Africa 2Health News:Using science to save lives of mothers and children in Africa 3Health News:Using science to save lives of mothers and children in Africa 4
... Plate is a semi-rigid system intended ... The Slim-LOC is based on the ... current market technology. The Slim-LOCTM system ... instrumentation. Reduced width (16 mm), low ...
... SC-Acufix anterior cervical plate system is a ... integrated swivel, which provides for consistent, reliable ... bone screw disengagement or backout. This innovative ... locking screw. Simply implant your screws and ...
... a leading provider of telemedicine solutions. ... state-of-the-art technology deliver accurate, reliable and ... professionals and clients in improving outcomes. ... ECG technology to gather patient data, ...
... is a high performance temperature controlled shaker ... shaking speed and incubation time are fully ... parameters are displayed on the LCD in ... below the microplates provide uniform incubation with ...
Medicine Products: